BR112017017396A2 - derivados substituídos de nucleosídeos substituídos úteis como agentes anticancerígenos - Google Patents

derivados substituídos de nucleosídeos substituídos úteis como agentes anticancerígenos

Info

Publication number
BR112017017396A2
BR112017017396A2 BR112017017396A BR112017017396A BR112017017396A2 BR 112017017396 A2 BR112017017396 A2 BR 112017017396A2 BR 112017017396 A BR112017017396 A BR 112017017396A BR 112017017396 A BR112017017396 A BR 112017017396A BR 112017017396 A2 BR112017017396 A2 BR 112017017396A2
Authority
BR
Brazil
Prior art keywords
substituted
anticancer agents
derivatives useful
nucleoside
substituted derivatives
Prior art date
Application number
BR112017017396A
Other languages
English (en)
Inventor
Yuanjin Rui Eugene
James Mcalpine Indrawan
Howard Tatlock John
James Wythes Martin
Ann Mctigue Michele
Bich Tran-Dube Michelle
Arnold Kumpf Robert
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR112017017396A2 publication Critical patent/BR112017017396A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom

Abstract

a presente invenção refere-se a compostos de fórmula geral (i): processos para a preparação destes compostos, a composições contendo estes compostos e a usos destes compostos.
BR112017017396A 2015-02-24 2016-02-15 derivados substituídos de nucleosídeos substituídos úteis como agentes anticancerígenos BR112017017396A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562119932P 2015-02-24 2015-02-24
US201562213801P 2015-09-03 2015-09-03
US201662279209P 2016-01-15 2016-01-15
PCT/IB2016/050803 WO2016135582A1 (en) 2015-02-24 2016-02-15 Substituted nucleoside derivatives useful as anticancer agents

Publications (1)

Publication Number Publication Date
BR112017017396A2 true BR112017017396A2 (pt) 2018-04-03

Family

ID=55451515

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017017396A BR112017017396A2 (pt) 2015-02-24 2016-02-15 derivados substituídos de nucleosídeos substituídos úteis como agentes anticancerígenos

Country Status (29)

Country Link
US (1) US10428104B2 (pt)
EP (1) EP3262057B1 (pt)
JP (1) JP6584521B2 (pt)
KR (1) KR20170119705A (pt)
CN (1) CN107278205A (pt)
AU (2) AU2016225133B2 (pt)
BR (1) BR112017017396A2 (pt)
CA (1) CA2921314A1 (pt)
CL (1) CL2017002155A1 (pt)
CO (1) CO2017008403A2 (pt)
CR (1) CR20170384A (pt)
CU (1) CU20170105A7 (pt)
DO (1) DOP2017000195A (pt)
EA (1) EA031895B1 (pt)
ES (1) ES2792899T3 (pt)
GT (1) GT201700189A (pt)
IL (1) IL253637A0 (pt)
MX (1) MX2017010844A (pt)
NI (1) NI201700095A (pt)
PE (1) PE20171449A1 (pt)
PH (1) PH12017501413A1 (pt)
SG (1) SG11201706050WA (pt)
SV (1) SV2017005514A (pt)
TN (1) TN2017000357A1 (pt)
TW (1) TWI622595B (pt)
UA (1) UA118315C2 (pt)
UY (1) UY36564A (pt)
WO (1) WO2016135582A1 (pt)
ZA (1) ZA201705092B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR104326A1 (es) 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
TW202321249A (zh) 2015-08-26 2023-06-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６－６雙環芳香環取代之核苷類似物
TN2018000310A1 (en) * 2016-03-10 2020-01-16 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as prmt5 inhibitors
WO2017153186A1 (en) 2016-03-10 2017-09-14 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as prmt5 inhibitors
MX2019002959A (es) 2016-09-14 2019-07-04 Janssen Pharmaceutica Nv Inhibidores biciclicos condensados de la interaccion de menina-mll.
EP3512857B1 (en) 2016-09-14 2021-02-24 Janssen Pharmaceutica NV Spiro bicyclic inhibitors of menin-mll interaction
MA46341A (fr) * 2016-10-03 2019-08-07 Janssen Pharmaceutica Nv Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5
EP3555103B1 (en) 2016-12-15 2021-09-22 Janssen Pharmaceutica NV Azepane inhibitors of menin-mll interaction
WO2018152548A1 (en) * 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018152501A1 (en) * 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
EA201990851A1 (ru) 2017-02-24 2019-09-30 Янссен Фармацевтика Нв Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
TN2019000212A1 (en) 2017-02-27 2021-01-07 Janssen Pharmaceutica Nv Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor
WO2018160855A1 (en) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
PT3665179T (pt) * 2017-08-09 2021-09-10 Prelude Therapeutics Inc Inibidores seletivos da proteína arginina metiltransferase 5 (prmt5)
JP7328218B2 (ja) * 2017-10-26 2023-08-16 プレリュード セラピューティクス，インコーポレイティド タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤
AU2018379456B2 (en) 2017-12-08 2022-11-24 Janssen Pharmaceutica Nv Novel spirobicyclic analogues
JP7282778B2 (ja) 2017-12-13 2023-05-29 ルピン・リミテッド Ｐｒｍｔ５阻害剤としての置換二環式複素環式化合物
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
US10711007B2 (en) 2018-03-14 2020-07-14 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
MX2020009555A (es) 2018-03-14 2021-01-20 Prelude Therapeutics Inc Inhibidores selectivos de proteina arginina-metiltransferasa 5 (prmt5).
US20210309687A1 (en) * 2018-08-07 2021-10-07 Merck Sharp & Dohme Corp. Prmt5 inhibitors
JP2022521491A (ja) * 2019-02-13 2022-04-08 プレリュード・セラピューティクス・インコーポレイテッド タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤
MX2021011524A (es) * 2019-03-25 2021-12-15 California Inst Of Techn Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos.
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用ｐｒｍｔ５抑制劑治療癌症之方法
HRP20231673T1 (hr) 2019-06-10 2024-03-15 Lupin Limited Inhibitori prmt5
CA3138349A1 (en) 2019-06-12 2020-12-17 Jonas VERHOEVEN Novel spirobicyclic intermediates
US20220395508A1 (en) 2019-10-22 2022-12-15 Lupin Limited Pharmaceutical combination of prmt5 inhibitors
AU2020394887A1 (en) 2019-12-03 2022-06-16 Lupin Limited Substituted nucleoside analogs as PRMT5 inhibitors
US11905292B2 (en) 2020-08-18 2024-02-20 Incyte Corporation Process and intermediates for preparing a JAK inhibitor
CA3192055A1 (en) 2020-08-18 2022-02-24 Incyte Corporation Process and intermediates for preparing a jak1 inhibitor
US20240101589A1 (en) * 2020-10-08 2024-03-28 Strom Therapeutics Limited Inhibitors of mettl3
CN112679505B (zh) * 2020-12-25 2022-04-22 杭州澳赛诺生物科技有限公司 一种4-甲基-7H-吡咯并[2,3-d]嘧啶的合成方法
WO2022153161A1 (en) 2021-01-14 2022-07-21 Pfizer Inc. Treatment of cancer using a prmt5 inhibitor
WO2023017152A1 (en) * 2021-08-13 2023-02-16 Albert-Ludwigs-Universität Freiburg Specific small molecule inhibitors that block kmt9 methyltransferase activity and function

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646128A (en) * 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
US5795977A (en) * 1989-09-15 1998-08-18 Metabasis Therapeutics, Inc. Water soluble adenosine kinase inhibitors
US5864033A (en) * 1989-09-15 1999-01-26 Metabasis Therapeutics, Inc. Adenosine kinase inhibitors
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
GB9813554D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
US6831069B2 (en) * 1999-08-27 2004-12-14 Ribapharm Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs
WO2004016635A2 (en) * 2002-08-15 2004-02-26 Cv Therapeutics, Inc. Partial and full agonists of a1 adenosine receptors
EA201190178A1 (ru) * 2009-03-20 2012-06-29 Алиос Биофарма, Инк. Замещённые нуклеозидные и нуклеотидные аналоги
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
US9416154B2 (en) * 2011-07-13 2016-08-16 Merck Sharp & Dohme Corp. 5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013044030A1 (en) * 2011-09-23 2013-03-28 Enanta Pharmaceuticals, Inc. 2'-chloroacetylenyl substituted nucleoside derivatives
EP3160477A4 (en) * 2014-06-25 2018-07-04 Epizyme, Inc. Prmt5 inhibitors and uses thereof
AR104326A1 (es) * 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
AU2016301188A1 (en) * 2015-08-06 2018-02-15 Chimerix, Inc. Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents

Also Published As

Publication number Publication date
AU2018278842A1 (en) 2019-01-03
NI201700095A (es) 2017-10-31
CO2017008403A2 (es) 2017-10-31
UA118315C2 (uk) 2018-12-26
CA2921314A1 (en) 2016-08-24
MX2017010844A (es) 2017-12-07
EP3262057B1 (en) 2020-04-15
ES2792899T3 (es) 2020-11-12
CR20170384A (es) 2017-11-16
EA201791563A1 (ru) 2018-01-31
EA031895B1 (ru) 2019-03-29
PE20171449A1 (es) 2017-10-02
JP2018510850A (ja) 2018-04-19
UY36564A (es) 2016-09-30
TW201643176A (zh) 2016-12-16
TWI622595B (zh) 2018-05-01
TN2017000357A1 (en) 2019-01-16
US10428104B2 (en) 2019-10-01
SV2017005514A (es) 2018-04-11
CU20170105A7 (es) 2017-10-05
AU2016225133B2 (en) 2018-11-29
SG11201706050WA (en) 2017-09-28
DOP2017000195A (es) 2017-10-15
ZA201705092B (en) 2019-06-26
PH12017501413A1 (en) 2018-01-29
KR20170119705A (ko) 2017-10-27
JP6584521B2 (ja) 2019-10-02
IL253637A0 (en) 2017-09-28
AU2016225133A1 (en) 2017-08-10
US20160244475A1 (en) 2016-08-25
CL2017002155A1 (es) 2018-05-11
EP3262057A1 (en) 2018-01-03
CN107278205A (zh) 2017-10-20
WO2016135582A1 (en) 2016-09-01
GT201700189A (es) 2019-06-10

Similar Documents

Publication Publication Date Title
BR112017017396A2 (pt) derivados substituídos de nucleosídeos substituídos úteis como agentes anticancerígenos
CO2018013105A2 (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
DOP2017000298A (es) Reguladores de nrf2
CO2017013229A2 (es) Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril)piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
BR112017006305A2 (pt) compostos heteroarila como inibidores de btk e usos dos mesmos
CR20150370A (es) Compuestos antivirales
BR112016028773A2 (pt) processos para preparação de compostos antivirais
BR112016014020A8 (pt) moduladores de tetra-hidropiridopirazinas de gpr6.
MX2017014035A (es) Formas solidas novedosas.
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
CL2018001210A1 (es) Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico.
EA201790570A1 (ru) Модуляторы р2х7
BR112018006314A2 (pt) composto da fórmula, composição, uso de composto da fórmula, método de combate a fungos fitopatogênicos e semente revestida
GT201600066A (es) Composiciones y métodos para inhibir la expresión del gen alas1
BR112016018418A2 (pt) Composto, uso do mesmo, e composição farmacêutica
BR112017012007A2 (pt) compostos orgânicos
CL2017002148A1 (es) Derivados de tetrahidropiranil benzamida
ECSP17063489A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07H 19/14 , C07H 19/167 , C07H 19/24 , A61K 31/52

Ipc: A61K 31/52 (2006.01), C07H 19/167 (2006.01), C07H

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements